Product Details
1/EA
$4,554.06
In StockAdditional Information
| Product Name | Zirabev 25Mg/Ml 16Ml Sdv 1/Ea |
| Active Ingredient | Bevacizumab-bvzr (biosimilar) |
| Mechanism of Action | Binds to VEGF-A, inhibiting angiogenesis and tumor blood vessel formation |
| Strength | 25 mg/mL |
| Volume | 16 mL (single-dose vial) |
| Route of Administration | Intravenous infusion |
| Dosing Frequency | Every 2 or 3 weeks depending on cancer type and regimen |
| Common Side Effects | Hypertension, proteinuria, fatigue, bleeding, gastrointestinal discomfort |
| Serious Adverse Effects | Gastrointestinal perforation, arterial thromboembolism, delayed wound healing, nephrotic syndrome |
| Precautions | Avoid in patients with recent major surgery; monitor for thromboembolic events |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F), protect from light, do not freeze or shake |
| Packaging | Single-dose vial (SDV) |
| Uses | Metastatic colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma, renal cell carcinoma, cervical cancer |
Description
Zirabev 25 mg/mL (16 mL single-dose vial) is a biosimilar of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). It is used in the treatment of multiple cancers, including metastatic colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma, renal cell carcinoma, and cervical cancer. By inhibiting VEGF, Zirabev reduces angiogenesis, limiting tumor blood supply and slowing disease progression.
The mechanism of action involves binding to VEGF-A, preventing its interaction with VEGF receptors on endothelial cells. This inhibition suppresses the formation of new blood vessels in tumors, reducing oxygen and nutrient delivery essential for cancer growth. Zirabev is administered via intravenous infusion and is often combined with chemotherapy for enhanced therapeutic efficacy.
Administration requires careful infusion rate control to minimize infusion-related reactions. Common adverse effects include hypertension, proteinuria, delayed wound healing, and increased risk of bleeding. Serious complications such as gastrointestinal perforation, arterial thromboembolic events, and nephrotic syndrome necessitate monitoring.
Frequently Asked Questions (FAQs)
The cost of ZIRABEV 25MG/ML 16ML SDV 1/EA is $$4,554.06
ZIRABEV 25MG/ML 16ML SDV 1/EA is manufactured by Pfizer.
You can purchase ZIRABEV 25MG/ML 16ML SDV 1/EA on our website at https://supplies.pipelinemedical.com/product/detail/zirabev-sf-25mg-ml-16ml-651295